Anti-inflammatory activity profile of JANEX-1 in preclinical animal models.
We examined the biologic activity of the rationally designed JAK3 inhibitor, JANEX-1, in several cellular and animal models of inflammation. Notably, JANEX-1 exhibited potent anti-inflammatory activity in each of these preclinical models, including mouse models of peritonitis, colitis, cellulitis, and systemic inflammatory response syndrome. Therefore, JANEX-1 may prove useful as a broad-spectrum anti-inflammatory agent. The present study may provide the basis for new and effective treatment as well as prevention programs for inflammatory disorders.
Uckun
Fatih M
FM
Parker Hughes Cancer Center, 2848 Patton Road, St. Paul, MN 55113, USA. fatih_uckun@ih.org
Tibbles
Heather
H
Ozer
Zahide
Z
Qazi
Sanjive
S
Vassilev
Alexei
A
D000208:Acute Disease; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002460:Cell Line; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D006614:Hindlimb / Q000187:drug effects; D006801:Humans; D053616:Janus Kinase 3 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000201:enzymology; D051379:Mice; D009569:Nitric Oxide / Q000096:biosynthesis; D011799:Quinazolines / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects; D018746:Systemic Inflammatory Response Syndrome / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D000893:Anti-Inflammatory Agents; D008070:Lipopolysaccharides; D011799:Quinazolines; D051197:Toll-Like Receptor 4; D014409:Tumor Necrosis Factor-alpha; C116180:WHI P131; D009569:Nitric Oxide; D053616:Janus Kinase 3